Search This Blog

Wednesday, July 1, 2026

Can-Fite BioPharma's Namodenoson meets primary safety endpoint in Phase 2a

Can-Fite BioPharma's Namodenoson meets primary safety endpoint in Phase 2a advanced pancreatic cancer study

  • Company plans Phase 2b trial combining Namodenoson with chemotherapy after Phase 2a showed durable survival outcomes.
Posted by at

No comments:

Post a Comment

Note: Only a member of this blog may post a comment.

Subscribe to: Post Comments (Atom)